Intensity Therapeutics Inc (INTS): Next-Year EPS Estimate 35.16%
As of 2026-10-10, Intensity Therapeutics Inc (INTS) has a next-year EPS growth estimate of 35.16%. Featured in our EPS revision report on 2026-08-20.
On 2026-08-18, analyst consensus for INTS's next-year EPS growth shifted from 30.36% to 35.16% — a positive change of 4.80 percentage points. The revised estimate has been sustained across 49 subsequent trading sessions. Current-year growth is projected at 59.46%.
What's Driving This
INTS has been rising alongside an improved next-year EPS growth estimate, now at 35
Generated 2026-09-22 from news as of 2026-09-22
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 35.16%
- EPS growth this year
- 59.46%
- EPS next quarter (est)
- -$0.99
- Last price
- $3.63
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-10 | 35.16% | 59.46% | -$0.99 | $3.63 |
| 2026-10-09 | 35.16% | 59.46% | -$0.99 | $3.63 |
| 2026-10-08 | 35.16% | 59.46% | -$0.99 | $3.68 |
| 2026-10-07 | 35.16% | 59.46% | -$0.99 | $3.80 |
| 2026-10-06 | 35.16% | 59.46% | -$0.99 | $3.55 |
| 2026-10-05 | 35.16% | 59.46% | -$0.99 | $3.45 |
| 2026-10-04 | 35.16% | 59.46% | -$0.99 | $3.44 |
| 2026-10-03 | 35.16% | 59.46% | -$0.99 | $3.44 |
| 2026-10-02 | 35.16% | 59.46% | -$0.99 | $3.44 |
| 2026-10-01 | 35.16% | 59.46% | -$0.99 | $3.21 |
| 2026-09-30 | 35.16% | 59.46% | -$0.99 | $3.37 |
| 2026-09-29 | 35.16% | 59.46% | -$0.99 | $3.42 |
| 2026-09-28 | 35.16% | 59.46% | -$0.99 | $3.65 |
| 2026-09-27 | 35.16% | 59.46% | -$0.99 | $3.80 |
| 2026-09-25 | 35.16% | 59.46% | -$0.99 | $3.80 |
| 2026-09-24 | 35.16% | 59.46% | -$0.99 | $3.89 |
| 2026-09-23 | 35.16% | 59.46% | -$0.99 | $4.10 |
| 2026-09-22 | 35.16% | 59.46% | -$0.99 | $4.01 |
| 2026-09-21 | 35.16% | 59.46% | -$0.99 | $4.02 |
| 2026-09-20 | 35.16% | 59.46% | -$0.99 | $4.11 |
| 2026-09-18 | 35.16% | 59.46% | -$0.99 | $4.11 |
| 2026-09-17 | 35.16% | 59.46% | -$0.99 | $3.88 |
| 2026-09-16 | 35.16% | 59.46% | -$0.99 | $3.81 |
| 2026-09-15 | 35.16% | 59.46% | -$0.99 | $3.81 |
| 2026-09-14 | 35.16% | 59.46% | -$0.99 | $3.98 |
| 2026-09-13 | 35.16% | 59.46% | -$0.99 | $4.02 |
| 2026-09-11 | 35.16% | 59.46% | -$0.99 | $4.02 |
| 2026-09-10 | 35.16% | 59.46% | -$0.99 | $4.04 |
| 2026-09-09 | 35.16% | 59.46% | -$0.99 | $4.02 |
| 2026-09-08 | 35.16% | 59.46% | -$0.99 | $4.09 |
Reports Featuring INTS
Screen Performance
Aggregate stats across all 2077 tickers our top-EPS-revision screen has flagged over the past 192 days.
- Median return since detection
- -0.9%
- % of tickers in the green
- 47%
- Median return on winners
- +23.2%
- Large revisions captured
- 1848
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Intensity Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-10-10, Intensity Therapeutics Inc (INTS) has a next-year EPS growth estimate of 35.16%, based on analyst consensus.
When was the latest EPS estimate revision for INTS?▾
The most recent revision occurred on 2026-08-18, when analysts adjusted the next-year EPS growth estimate from 30.36% to 35.16%.
What sector and industry does Intensity Therapeutics Inc belong to?▾
Intensity Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. INTS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Intensity Therapeutics Inc (INTS) appears here because it was detected by our daily top-EPS-revision-performer screen.